Hinge Health, Inc. Stock Price, News & Analysis

Hinge Health (NYSE: HNGE) announced a $250 million share repurchase program approved by its board on November 10, 2025. The company reported $108 million cash from operations and $118 million free cash flow in the first nine months of 2025, and held nearly $500 million in cash and investments at end of Q3 2025.

Repurchases may occur in the open market, via privately negotiated transactions, or under Rule 10b5-1 plans; timing and amounts are at the company’s discretion. The program may be funded from existing cash and ongoing operations and does not obligate any specific purchases.

Hinge Health (NYSE:HNGE) announced two AI care tools on October 21, 2025: Movement Analysis, which uses TrueMotion® computer vision to capture joint angles, symmetry, and endurance to create new Hinge Scores for joint health, and Robin, an AI Care Assistant that provides 24/7 support and initially detects pain flare-ups, gathers details, shares resources, and summarizes for a member's physical therapist. The company also published its AI care principles emphasizing thoughtful design, responsible building, and complementing human care, with commitments to ethics, privacy, transparency, and continuous improvement.

Hinge Health (NYSE:HNGE) has scheduled its Q3 2025 earnings release for November 4, 2025, after U.S. market hours. The company will host an earnings conference call at 1:30 PM PT (4:30 PM ET) on the same day to discuss financial results and provide guidance.

Investors can access the live audio webcast through the company's investor relations website at ir.hingehealth.com. A replay will be made available on the same platform after the call concludes.

Hinge Health (NYSE: HNGE) reported strong Q2 2025 financial results, with revenue surging 55% year-over-year to $139.1 million. The company demonstrated robust growth metrics, including a 32% increase in client base to 2,359 and LTM calculated billings of $568.4 million, up 55% from Q2 2024.

The company's financial performance showed mixed results, with a GAAP loss from operations of $580.7 million, largely due to $591.0 million in stock-based compensation expense. However, non-GAAP income from operations was positive at $26.1 million. The company maintained strong liquidity with $415.1 million in cash and equivalents.

Looking ahead, Hinge Health provided guidance for Q3 2025 with expected revenue between $141-143 million and full-year 2025 revenue projected at $548-552 million, representing 41% year-over-year growth at the midpoint.

Hinge Health (NYSE:HNGE) has scheduled its second quarter 2025 financial results announcement for August 5, 2025, after market close. The company will host an earnings conference call at 1:30 PM PT / 4:30 PM ET on the same day to discuss its quarterly performance and provide guidance.

Investors can access the live audio webcast through the company's investor relations website at ir.hingehealth.com. A replay of the webcast will be made available on the website following the presentation.

Hinge Health (NYSE:HNGE) has launched HingeSelect, a high-performance provider network for musculoskeletal (MSK) care that combines AI-powered digital exercise therapy with access to in-person care providers at up to 50% below PPO rates. The platform features unified care delivery, where technology and in-house orthopedic physicians triage patients and direct them to appropriate evidence-based treatments. Members can access orthopedic specialists within 48 hours and schedule in-person appointments directly through the app. HingeSelect addresses key healthcare challenges including long appointment wait times (averaging 20 days), variable adherence to evidence-based care among providers, and high costs. The platform offers a curated network of local physical therapists, imaging centers, and physicians, with bundled pricing for transparent, predictable costs and reduced member cost sharing.

Hinge Health (NYSE: HNGE) announced significant cost savings from a medical claims analysis, showing $2,343 average savings per member annually and a 2.4x ROI for fully insured health plan members using its digital musculoskeletal (MSK) platform. The study, validated by Gallagher, analyzed 4,788 health plan members and revealed reduced healthcare service utilization, with 44% of claims reductions attributed to avoided surgeries. The analysis compared Hinge Health participants with a matched control group using a claims database of over 100 million commercially insured lives from 2017 to 2023. The results reinforce previous studies demonstrating consistent 2x+ ROI across various demographics, including multi-employer and Medicare populations.

Hinge Health (NYSE: HNGE) has announced the pricing of its Initial Public Offering (IPO), offering 13,666,000 shares of Class A common stock at $32.00 per share. The offering consists of 8,522,528 shares from Hinge Health and 5,143,472 shares from selling stockholders. Trading is set to begin on the NYSE on May 22, 2025, under the ticker "HNGE".

The selling stockholders have granted underwriters a 30-day option to purchase up to 2,049,900 additional shares. The company plans to use the proceeds primarily to cover tax obligations related to restricted stock units. Morgan Stanley, Barclays, and BofA Securities are serving as lead book-running managers for the offering.